Algernon Pharmaceuticals Inc. hits co-primary endpoint in Phase 2 study of Ifenprodil for idiopathic pulmonary fibrosis and chronic cough treatment proactiveinvestors.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from proactiveinvestors.com Daily Mail and Mail on Sunday newspapers.
Algernon Pharmaceuticals Hits Co-Primary Endpoint in its Phase 2 Study of Ifenprodil for Idiopathic Pulmonary Fibrosis and Chronic Cough | Comunicados | Edición USA efe.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from efe.com Daily Mail and Mail on Sunday newspapers.
AX-8 reduces cough frequency and improves patient-reported outcomes in patients with chronic cough Axalbion, a clinical-stage biopharmaceutical company focused on developing novel medicines to treat